Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: Requirements for subtype selectivity and intrinsic activity modulation

Journal of Medicinal Chemistry

Volumn 46, Issue 8, 2003, Pages 1429-1439

  Rivara, Silvia ^a   Mor, Marco ^a   Silva, Claudia ^a   Zuliani, Valentina ^a   Vacondio, Federica ^a   Spadoni, Gilberto ^b   Bedini, Annalida ^b   Tarzia, Giorgio ^b   Lucini, Valeria ^c   Pannacci, Marilou ^c   Fraschini, Franco ^c   Vincenzo Plazzi, Pier ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXYBENZYLBENZOFURAN; BENZOFURAN DERIVATIVE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; MELATONIN RECEPTOR AGONIST; MELATONIN RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SYNTHESIS; HYPOTHESIS; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; RELIABILITY; STATISTICAL MODEL;

LIGANDS; MELATONIN; MODELS, MOLECULAR; MODELS, STATISTICAL; PYRROLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN;

EID: 0037431390     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020982d     Document Type: Article

References (69)

1. Cassone, V. M. Effects of melatonin on vertebrate circadian system. Trends Neurosci. 1990, 13, 457-464.
2. Shochat, T.; Haimov, I.; Lavie, P. Melatonin - the key to the gate of sleep. Ann. Med. 1998, 30, 109-114.
3. Pang, S. F.; Li, L.; Ayre, E. A.; Pang, C. S.; Lee, P. P. N.; Xu, R. K.; Chow, P. H.; Yu, Z. H.; Shiu, S. Y. W. Neuroendocrinology of melatonin in reproduction: recent developments. J. Chem. Neuroanat. 1998, 14, 157-166.
4. Doolen, S.; Krause, D. N.; Dubocovich, M. L.; Duckles, S. P. Melatonin mediates two distinct responses in vascular smooth muscle. Eur. J. Pharmacol. 1998, 345, 67-69.
5. Arangino, S.; Cagnacci, A,; Angiolucci, M.; Vacca, A. M.; Longu, G.; Volpe, A.; Melis, G. B. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am. J. Cardiol. 1999, 83, 1417-1419.
6. Motilva, V.; Cabeza, J.; Alarcón de la Lastra, C. New issues about melatonin and its effects on the digestive System. Curr. Pharm. Des. 2001, 7, 909-931.
7. Nowak, J. Z.; Zawilska, J. B. Melatonin and its physiological and therapeutic properties. Pharm. World Sci. 1998, 20, 18-27.
8. Wetterberg, L. Melatonin and clinical application. Reprod., Nutr., Dev. 1999, 39, 367-382.
9. Li, P.-K.; Witt-Enderby, P. A. Melatonin receptors as potential targets for drug discovery. Drugs Future 2000, 25, 945-957.
10. Reiter, R. J.; Tan, D. X.; Cabrera, J.; D'Arpa, D.; Sainz, R. M.; Mayo, J. C.; Ramos, S. The oxidant/antioxidant network: role of melatonin. Biol. Signals Recept. 1999, 8, 56-63.
11. Lipartiti, M.; Franceschini, D.; Zanoni, R.; Gusella, M.; Giusti, P.; Cagnoli, C. M.; Kharlamov, A.; Manev, H. Neuroprotective effects of melatonin. Adv. Exp. Med. Biol. 1996, 398, 315-321.
12. Nelson, R. J.; Drazen, D. L. Melatonin mediates seasonal adjustments in immune function. Reprod., Nutr., Dev. 1999, 39, 383-398.
13. Liu, R. Y.; Zhou, J. N.; van Heerikhuize, J.; Hofman, M. A.; Swaab, D. F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to ageing, Alzheimer's desease, and apolipoprotein E-epsilon4/4 genotype. J. Clin. Endocrinol. Metab. 1999, 84, 323-327.
14. Nosjean, O.; Ferro, M.; Cogé, F.; Beauverger, P.; Henlin, J.-M.; Lefoulon, F.; Fauchère, J.-L.; Delagrange, P.; Canet, E.; Boutin, J. A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2000, 275, 31311-31317.
15. Smirnov, A. N. Nuclear Melatonin Receptors. Biochemistry (Moscow) 2001, 66, 19-26.
16. Paz Romero, M.; García-Pergañeda, A.; Guerrero, J. M.; Osuna, C. Membrane-bound calmodulin in Xenopus Laevis oocytes as a novel binding site for melatonin. FASEB J. 1998, 12, 1401-1408.
17. Sugden, D.; Chong, N. W. S.; Lewis, D. F. V. Structural requirements at the melatonin receptor. Br. J. Pharmacol. 1995, 114, 618-623.
18. Grol, C. J.; Jansen, J. M. The high affinity melatonin binding site probed with conformationally restricted ligands-II. Homology modeling of the receptor. Bioorg. Med. Chem. 1996, 4, 1333-1339.
19. Navajas, C.; Kokkola, T.; Poso, A.; Honka, N.; Gynther, J.; Laitinen, J. T. A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor. Eur. J. Pharmacol. 1996, 304, 173-183.
20. 1aβ melatonin receptor. Biochem. Biophys. Res. Commun. 1997, 239, 418-423.
21. 1 receptor. Biochem. Biophys. Res. Commun. 2001, 282, 1229-1236.
22. Nelson, C. S.; Ikeda, M.; Gompf, H. S.; Robinson, M. L.; Fuchs, N. K.; Yoshioka, T.; Neve, K. A.; Allen, C. N. Regulation of melatonin 1a receptor signaling and trafficking by asparagine-124. Mol. Endocrinol. 2001, 15, 1306-1317.
23. Dubocovich, M. L.; Yun, K.; Al-Ghoul, W. M.; Benloucif, S.; Masana, M. I. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998, 12, 1211-1220.
24. Hunt, A. E.; Al-Ghoul, W. M.; Gillitte, M. U.; Dubocovich, M. L. Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol.: Cell Physiol. 2001, 280, C110-C118.
25. Drazen, D. L.; Nelson, R. J. Melatonin receptor subtype MT2 (Mel1b) and not mt1 (Mel1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 2001, 74, 178-184.
26. Spadoni, G.; Balsamini, C.; Diamantini, G.; Di Giacomo, B.; Tarzia, G.; Mor, M.; Plazzi, P. V.; Rivara, S.; Lucini, V.; Nonno, R.; Pannacci, M.; Fraschini, F.; Stankov, B. M. Conformationally restrained melatonin analogs: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. J. Med. Chem. 1997, 40, 1990-2002.
27. Tarzia, G.; Diamantini, G.; Di Giacomo, B.; Spadoni, G.; Esposti, D.; Nonno, R.; Lucini, V.; Pannacci, M.; Fraschini, F.; Stankov, B. M. 1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogs. J. Med. Chem. 1997, 40, 2003-2010.
28. Copinga, S.; Tepper, P. G.; Grol, C. J.; Horn, A. S.; Dubocovich, M. L. 2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents. J. Med. Chem. 1993, 36, 2891-2898.
29. Depreux, P.; Lesieur, D.; Mansour, H. A.; Morgan, P.; Howell, H. E.; Renard, P.; Caignard, D. H.; Pfeiffer, B.; Delagrange, P.; Guardiola, B.; Yous, S.; Demarque, A.; Adam, G.; Andrieux, J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J. Med. Chem. 1994, 37, 3231-3239.
30. Sugden, D. N-Acyl-3-amino-5-methoxychromans: a new series of non-indolic melatonin analogues. Eur. J. Pharmacol. 1994, 254, 271-275.
31. 125I]iodomelatonin binding sites. J. Med. Chem. 1995, 38, 2050-2060.
32. Mathé-Allainmat, M.; Gaudy, F.; Sicsic, S.; Dangy-Caye, A.-L.; Shen, S.; Bremont, B.; Benatalah, Z.; Langlois, M.; Renard, P.; Delagrange, P. Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. J. Med. Chem. 1996, 39, 3089-3095.
33. Garratt, P. J.; Travard, S.; Vonhoff, S.; Tsotinis, A.; Sugden, D. Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. J. Med. Chem. 1996, 39, 1797-1805.
34. Li, P.-K.; Chu, G.-H.; Gillen, M. L.; Witt-Enderby, P. A. Synthesis and receptor binding studies of quinolinic derivatives as melatonin receptor ligands. Bioorg. Med. Chem. Lett. 1997, 7, 2177-2180.
35. Davies, D. J.; Garratt, P. J.; Tocher, D. A.; Vonhoff, S.; Davies, J.; Teh, M. T.; Sugden, D. Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept-[b]indoles. J. Med. Chem. 1998, 41, 451-467.
36. Leclerc, V.; Fourmaintramx, E.; Depreux, P.; Lesieur, D.; Morgan, P.; Howell, H. E.; Renard, P.; Caignard, D. H.; Pfeiffer, B.; Delagrange, P.; Guardiola-Lemaitre, B.; Andrieux, J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. Bioorg. Med. Chem. 1998, 6, 1875-1887.
37. Charton, I.; Mamai, A.; Bennejean, C.; Renard, P.; Howell, E. H.; Guardiola-Lemaitre, B.; Delagrange, P.; Morgan, P. J.; Viaud, M.-C.; Guillaumet, G. Substituted oxigenated heterocycles and thio-analogues: synthesis and biological evaluation as melatonin ligands. Bioorg. Med. Chem. 2000, 8, 105-114.
38. Faust, R.; Garratt, P. J.; Jones, R.; Yeh, L.-K.; Tsotinis, A.; Panoussopoulou, M.; Calogeropoulou, T.; Teh, M.-T.; Sugden, D. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. J. Med. Chem. 2000, 43, 1050-1061.
39. Jellimann, C.; Mathé-Allainmat, M.; Andrieux, J.; Kloubert, S.; Boutin, J. A.; Nicolas, J.-P.; Bennejean, C.; Delagrange, P.; Langlois, M. Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors. J. Med. Chem. 2000, 43, 4051-4062.
40. Jansen, J. M.; Copinga, S.; Gruppen, G.; Molinari, E. J.; Dubocovich, M. L.; Grol, C. J. The high affinity melatonin binding site probed with conformationally restricted ligands - I. Pharmacophore and minireceptor models. Bioorg. Med. Chem. 1996, 4, 1321-1332.
41. Marot, C.; Chavatte, P.; Morin-Allory, L.; Viaud, M. C.; Guillaumet, G.; Renard, P.; Lesieur, D.; Michel, A. Pharmacophoric search and 3D-QSAR comparative molecular field analysis studies on agonists of melatonin sheep receptors. J. Med. Chem. 1998, 41, 4453-4465.
42. Teh, M. T.; Sugden, D. Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores. Naunyn.Schmiedeberg's Arch. Pharmacol. 1998, 358, 522-528.
43. Spadoni, G.; Mor, M.; Tarzia, G. Structure-affinity relationships of indole-based melatonin analogs. Biol. Signals Recept. 1999, 8, 15-23.
44. Mor, M.; Spadoni, G.; Di Giacomo, B.; Diamantini, G.; Bedini, A.; Tarzia, G.; Plazzi, P. V.; Rivara, S.; Nonno, R.; Lucini, V.; Pannacci, M.; Fraschini, F.; Stankov, B. M. Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. Bioorg. Med. Chem. 2001, 9, 1045-1057.
45. Spadoni, G.; Balsamini, C.; Diamantini, G.; Tontini, A.; Tarzia, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Nonno, R.; Lucini, V.; Pannacci, M.; Fraschini, F.; Stankov, B. M. 2-N-Acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists. J. Med. Chem. 2001, 44, 2900-2912.
46. Sicsic, S.; Serraz, I.; Andrieux, J.; Brémont, B.; Mathé-Allainmat, M.; Poncet, A.; Shen, S.; Langlois, M. Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study. J. Med. Chem. 1997, 40, 739-748.
47. Mor, M.; Rivara, S.; Silva, C.; Bordi, F.; Plazzi, P. V.; Spadoni, G.; Diamantini, G.; Balsamini, C.; Tarzia, G.; Fraschini, F.; Lucini, V.; Nonno, R.; Stankov, B. M. Melatonin receptor ligands: Synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study. J. Med. Chem. 1998, 41, 3831-3844.
48. 2 melatonin receptors. Med. Chem. Res. 1998, 8, 487-498.
49. 3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists. J. Med. Chem. 1998, 41, 3624-3634.
50. Nosjean, O.; Nicolas, J.-P.; Klupsch, F.; Delagrange, P.; Canet, E.; Boutin, J. A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem. Pharmacol. 2001, 61, 1369-1379.
51. 1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 355, 365-375.
52. Rivara, S.; Mor, M.; Spadoni, G.; Tarzia, G.; Vacondio, F.; Lucini, V.; Plazzi, P. V. QSAR and 3D-QSAR characterization of MT2 selective melatonin receptor antagonists. Presented at the Hungarian - German - Italian - Polish Joint Meeting on Medicinal Chemistry, Budapest, Hungary, September 2-6, 2001.
53. Jelliman, C.; Lefas-Le Gall, M.; Mathé-Allainmat, M.; Andrieux, J.; Sicsic, S.; Nicolas, J. P.; Boutin, J.; Delagrange, P.; Bennejan, C.; Renard, P.; Langlois, M. Design, sinthesis and biological evaluation of new melatoninergic compounds. Presented at the XVIth International Symposium on Medicinal Chemistry, Bologna, Italy, September 18-22, 2000; Poster PB98.
54. Wallez, V.; Durieux-Poissonnier, S.; Chavatte, P.; Boutin, J. A.; Audinot, V.; Nicolas, J.-P.; Bennejean, C.; Delagrange, P.; Renard, P.; Lesieur, D. Synthesis and structure - affinity - activity relationships of novel benzofuran derivatives as MT2 melatonin receptor selective ligands. J. Med. Chem. 2002, 45, 2788-2800.
55. Nonno, R.; Lucini, V.; Pannacci, M.; Mazzucchelli, C.; Angeloni, D.; Fraschini, F.; Stankov, B. M. Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells. Br. J. Pharmacol. 1998, 124, 485-492.
56. Nonno, R.; Pannacci, M.; Lucini, V.; Angeloni, D.; Fraschini, F.; Stankov, B. M. Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists. Br. J. Pharmacol. 1999, 127, 1288-1294.
57. 50) of an enzymatic reaction. Biochem Pharmacol. 1973, 22, 3099-3108.
58. Sybyl, version 6.8; Tripos Inc. (1699 South Hanley Rd): St. Louis, MO 63144; 2001.
59. Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. Validation of the general purpose Tripos 5.2 force field. J. Comput. Chem. 1989, 10, 982-1012.
60. Powell, M. J. D. Restart procedures for the conjugate gradient method. Math. Program. 1977, 12, 241-254.
61. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
62. Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules To Correlate and Predict Their Biological Activity. J. Med. Chem. 1994, 37, 4130-4146.
63. Klebe, G.; Abraham, U. Comparative Molecular Similarity Index Analysis (CoMSIA) To Study Hydrogen-Bonding Properties and To Score Combinatorial Libraries. J. Comput.-Aided Mol. Des. 1999, 13, 1-10.
64. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity-Rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
65. Hückel, Z. Quanten theoretische beiträge zum benzolproblem. I. Die electron enkonfiguration des benzols. Z. Phys. 1931, 70, 203-286.
66. Wold, S.; Ruhe, A.; Wold, H.; Dunn, W. J. The covariance problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J. Sci. Stat. Comput. 1984, 5, 735-743.
67. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quantum Struct.-Act. Relat. 1988, 7, 18-25.
68. Bush, B. L.; Nachbar, R. B. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J. Comput.-Aided Mol. Des. 1993, 7, 587-619.
69. Cruciani, G.; Clementi, S.; Baroni, M. Variable selection in PLS analysis. In 3D QSAR in Drug Design. Theory Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, The Netherlands, 1993; p 552.